Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101

NCT ID: NCT03644459

Last Updated: 2020-03-11

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-04-03
• Study Completion Date: 2020-08-31

Brief Summary

The purpose of this study is evaluate the pharmacokinetics, pharmacodynamics, immunogenicity and anti-tumor effect of of fully human anti - VEGF monoclonal antibody LY00101 and explore the potential prognostic and predictive biomarkers.

This study will not take into account the results of molecular-genetic tests of patients enrolled in the study

Detailed Description

Tumors can be inactive for years, until transformation of cells into an angiogenic phenotype occurs. This phenomenon is known as angiogenic switch. It is based on balance between inhibitors and activators of angiogenesis.

Multiple genetic changes and processes leading to malignancies, such as activation of oncogenes, can trigger angiogenic switch.

Simple diffusion of nutrients and oxygen normally occurs within not more than 1-2 mm of tumor tissue. For further growth, blood supply and development of the vasculature are necessary.

Angiogenesis level in a tumor and it's metastasis activity has correlation with density of microvessels in a primary tumor and significantly affects disease prognosis.

Angiogenesis in a body is regulated through Vascular endothelial growth factor (VEGF) and its receptors.

There is a unique binding pattern of corresponding receptors typical for all members of the VEGF family:

• VEGF-A binds with VEGFR1 and VEGFR2
• VEGF-B and PlGF bind and activate receptor VEGFR1 only
• VEGF-C and VEGF-D communicate with receptor VEGFR3 (Flt4), triggering lymphangiogenesis, and demonstrate activity correlated with VEGFR2.

According to studies, VEGFR1 binds to the ligand with the highest affinity, binding VEGF and inhibiting VEGF-mediated signaling.

The VEGF-VEGFR2 binder induces autophosphorylation (and partial dimerization) of the catalytic domain of the PI3K / v-akt signaling pathway receptor (Phosphoinositide 3-kinase / murine thymoma viral oncogene homolog - Akt or serine / threonine protein kinase B, PKB), as well as Raf and MAP2K, which further phosphorylate MAPK (Erk).

Monoclonal antibody LYN00101 is not only a potent inhibitor of VEGF, also blocks autocrine growth factor loops by inhibiting VEGF and VEGFR 1/2/3 receptors and effectively blocking neoangiogenesis.

The purpose of this study is evaluate the pharmacokinetics, pharmacodynamics, immunogenicity and anti-tumor effect of of fully human anti - VEGF monoclonal antibody LY00101 and explore the potential prognostic and predictive biomarkers.

This study will not take into account the results of molecular-genetic tests of patients enrolled in the study.

Conditions

Ovarian Cancer; Cervical Cancer; Colorectal Cancer; Stomach Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

LYN00101

Intravenous Infusion at the rate of 8 mg/kg of the patient's weight every 14 days.

Group Type: EXPERIMENTAL

LYN00101

Intervention Type: BIOLOGICAL

Concentrate for intravenous infusions (10 mg / ml) with Molecular Weight 150 - 151 kDa.

Each cycle of treatment consists of 24 weeks. Patients who enroll into this study will receive an infusion of assigned dose of LYN00101 biweekly. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 10mg/kg, starting from 8 mg/kg.

Interventions

LYN00101

Concentrate for intravenous infusions (10 mg / ml) with Molecular Weight 150 - 151 kDa.

Each cycle of treatment consists of 24 weeks. Patients who enroll into this study will receive an infusion of assigned dose of LYN00101 biweekly. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 10mg/kg, starting from 8 mg/kg.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• patients with histopathologically-documented, measurable or non measurable {evaluable}, advanced solid tumors refractory
• a life expectancy of >3 months
• ECOG performance status score of ≤ 2 at study entry
• able to provide written informed consent.
• use of effective contraceptive measures if procreative potential exists.
• an absolute neutrophil count ≥1500/mm3
• a hemoglobin level ≥ 9gm/dL
• a platelet count ≥100,000/mm3
• a total bilirubin level ≤1.5 x the ULN
• aspartate transaminase (AST) and alanine transaminase (ALT) levels ≤2.5 x the ULN or ≤5 x the ULN if known liver metastases
• adequate renal function, as defined by a serum creatinine level ≤1.5 x the ULN.

Exclusion Criteria

• patients with any active infection (nail bed induced fungal infections were excluded), chronic infections, and tuberculosis history.
• the females were pregnant, or lactating or showed positive urine pregnancy reaction during screening.
• patients with severe heart disease, heart failure, asthma, chronic obstructive pulmonary disease or neuropsychiatric diseases.
• uncontrolled diabetes or poor compliance with hypoglycemics;
• the presence of chronically unhealed wound or ulcers
• other chronic diseases, which, in the opinion of the investigator, could compromise safety of the patient or the integrity of study.
• newly-diagnosed or symptomatic brain metastases (patients with a history of brain metastases must have received definitive surgery or radiotherapy, be clinically stable, and not taking steroids for brain edema). Anticonvulsants are allowed.
• peritoneal carcinomatosis
• pregnancy (confirmed by serum beta human chorionic gonadotropin [ßHCG]) or breast-feeding (for female patients only).
• a known history or clinical evidence of a deep vein or arterial thrombosis, or pulmonary embolism
• less than six weeks from last infusion of any anti-VEGF monoclonal antibody therapy
• known history of human immunodeficiency virus infection (HIV).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Lynkcell Inc.

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

LY233-234V

Identifier Type: -

Identifier Source: org_study_id